key: cord-332654-nav15g8k
authors: Paniri, Alireza; Hosseini, Mohammad Mahdi; Rasoulinejad, Ahmad; Akhavan-Niaki, Haleh
title: Molecular effects and retinopathy induced by hydroxychloroquine during SARS-CoV-2 therapy: Role of CYP450 isoforms and epigenetic modulations
date: 2020-08-04
journal: Eur J Pharmacol
DOI: 10.1016/j.ejphar.2020.173454
sha: 
doc_id: 332654
cord_uid: nav15g8k

Antimalaria drugs such as chloroquine (CQ) and hydroxychloroquine (HCQ) have been administered to several inflammatory diseases including rheumatoid arthritis and systemic lupus erythematosus, and infectious diseases such as acquired immune deficiency syndrome and influenza. Recently, several patients infected with novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were given HCQ, and showed a discrepant response. HCQ inhibits SARS-CoV-2 cell entry, and inflammatory cascade by interfering with lysosomal and endosomal activities, and autophagy, impeding virus-membrane fusion, and inhibiting cytokine production resulted from inflammatory pathways activation. Despite ongoing administration of HCQ in a wide spectrum of disorders, there are some reports about several side effects, especially retinopathy in some patients treated with HCQ. Cytochrome P450 (CYP450) and its isoforms are the main metabolizers of HCQ and CQ. Pharmacokinetic properties of CYP enzymes are influenced by CYP polymorphism, non-coding RNAs, and epigenetic mechanisms such as DNA methylation, and histone acetylation. Accumulating evidence about side effects of HCQ in some patients raise the possibility that different response of patients to HCQ might be due to difference in their genome. Therefore, CYP450 genotyping especially for CYP2D6 might be helpful to refine HCQ dosage. Also, regular control of retina should be considered for patients under HCQ treatment. The major focus of the present review is to discuss about the pharmacokinetic and pharmacodynamic properties of CQ and HCQ that may be influenced by epigenetic mechanisms, and consequently cause several side effects especially retinopathy during SARS-CoV-2 therapy.

Potential antimalarial drugs such as chloroquine (CQ) and hydroxychloroquine (HCQ) have been long used to prophylaxis and treatment of malaria (Warhurst et al. 2003) . Although, administration of CQ and HCQ have extended to several inflammatory diseases such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and against some viruses including human immunodeficiency virus (HIV), and influenza (Chiang et al., 1996; Ooi et al., 2006) . The current pandemy of novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused a high morbidity and mortality with 17,189,755 confirmed cases and 670,256 deaths until July, 30, 2020 670,256 deaths until July, 30, (2020a . Recently several studies suggested that HCQ J o u r n a l P r e -p r o o f could be an effective agent to decrease the viral load, and ameliorate clinical manifestations of patients infected with SARS-CoV-2 Gautret et al., 2020) . Even though, clinical trial studies of HCQ in patients with SARS-CoV-2 showed inconsistent results about the effect of HCQ on decreasing patients' infection Gautret et al., 2020) .

There is some evidence that administration of HCQ gives rise to retinopathy in some patients affected with autoimmune diseases such as RA and SLE (Kobak & Deveci, 2010; Lee et al., 2015) . It's noteworthy that several risk factors including duration of use, exceeding of recommended dose (> 5 mg/kg per day (400 mg in an 80 Kg person)), and pre-existing retinal disease have been identified for ocular toxicity in patients who were under HCQ therapy. Correspondingly, there is also evidence that prolonged use of HCQ increases the risk of ocular toxicity, and high doses could lead to rapid changes in vision and consequently retinopathy development. The much higher doses of HCQ used in combat against viral infections such as SARS-CoV-2 (600 or 1000 mg daily dose) in comparison with its recommended doses for treatment of RA and SLE (200-400 mg/day) have raised the possibility of more remarkable retinopathy progression in SARS-CoV-2 patients under HCQ therapy (Mahase, 2020; Gautret et al., 2020; Pereira, 2020) . Furthermore, growing body of evidence demonstrated that several factors including CYP450 single nucleotide polymorphisms (SNPs), and epigenetic molecules such as non-coding RNAs (ncRNAs), DNA methylation and histone acetylation influenced the expression levels of CYP450, and consequently might influence HCQ metabolism. (Li et al., 2015; Zeng et al., 2017; Wang et al., 2019) . The major purpose of this review is to discuss the pharmacokinetic and pharmacodynamic characteristics of CQ and HCQ that may be influenced by epigenetic mechanisms including ncRNAs and CYP2D6 SNPs, and thereby cause several side effects such as cardiotoxicity, prolonged QT interval, gastrointestinal problems (like dyspepsia and abdominal cramps), central nervous system or skin disorders, and especially retinopathy.

Also, we review the advantage of personalized medicine to determining HCQ dosage regarding the unique genotype of patients for SARS-CoV-2 treatment.

properties (Rainsford et al., 2015) . Both drugs are appropriately distributed to aqueous cellular and intercellular compartments after oral administration, and have a prolonged residence time (one month in average) (Augustijns et al., 1992; Schrezenmeier & Dörner, 2020) . Table 1 summarizes the pharmacokinetic of these drugs. HCQ similar to CQ is absorbed by upper intestinal tract cells, and its renal clearance is 2.5 times less than CQ (HCQ: 21% versus CQ: 51%). The apparent volumes of distribution of HCQ are 47,257 L (calculated from plasma) and 5,500 L (calculated from blood), respectively which would indicate that HCQ accumulates in other compartments. CQ has an apparent volume of distribution equal to 65,000 L (calculated from plasma), and 15,000 L (calculated from blood) (Cutler et al, 1988; Tett et al., 1990) . Also, un-metabolized excretion of HCQ (62%) is approximately similar to CQ (58%) (Collins et al., 2018; Cutler et al., 1988) . Accumulating evidence revealed that HCQ similar to CQ is excreted into breast milk, and moves across the placenta to exert its pharmacokinetic effects on fetus (Law et al., 2008; Motta et al., 2005) .

Recently, HCQ was mostly applied to treat a wide spectrum of disorders including connective tissue diseases, and autoimmune disorders in comparison with CQ due to lower toxicity, and side effects Stokkermans & Trichonas, 2019) . Previous studies on animal models revealed that HCQ may be distributed in a wide spectrum of tissues including adrenal, spleen, lung, liver, kidney, heart, retina-choroid, skin, pituitary, muscle, brain, fat, and bone (McChesney, 1983; McChesney et al., 1967) .

Several studies conducted on pharmacodynamic of HCQ proposed a multi-pathway model for HCQ effects (Fox, 1996; Kyburz et al., 2006) . Obtained results showed that the major mechanism of HCQ action is modulation (elevation) of cellular pH (2020b; Fox, 1993) . HCQ properly passes through the lysosomal membrane, and inhibits several processes including protein degradation, antigen presentation, and toll-like receptor (TLR) signalling by increasing the pH of lysosome and endosome from 4 to 6 (Fox, 1993; Kyburz et al, 2006) . Elevated levels of pH in lysosome lead to metabolites deposition, and impediment of antigen presentation mediated by major histocompatibility complex (MHC) class II through lysosomal acidic hydrolysis blockage (Fox, 1996; Schrezenmeier & Dörner, 2020) . Inhibition of antigen presenting cells including dendritic cells , macrophages, and B cells prevents the process of T cells activation mediated by MHC ( Fig 1A) (Ireland & Unanue, 2011) . Several studies reported that lysosomal enzymes blockage prolongates the degradation of macromolecules in lysosome, and thereby progressively converts them into lipofuscin (Ding J o u r n a l P r e -p r o o f Sundelin & Terman, 2002) . Lipofuscins are brown-yellow accumulated metabolites such as inclusions which appear gradually with age (Terman & Brunk, 2004) .

On the other hand, HCQ prevents from autoantigen presentation mediated by MHC II on antigen presenting cells due to obstruction of autoantigenic proteins degradation (Yoon et al., 2013) . Furthermore, HCQ exerts its anti inflammatory effects via increasing the pH levels of endosome which is essential in TLR signaling in innate immunity (Thwaites et al., 2014) .

Also, HCQ could inhibit the innate immunity by binding to TLR ligands including DNA and single strand RNA (ssRNA) which interact with TLR9 and TLR7, respectively (Schrezenmeier & Dörner, 2020; Thwaites et al., 2014) . Strinkingly, several recent studies suggested that HCQ acts as an anti inflammatory agent through disruption in cyclic GMP-AMP (cGAMP) synthase (cGAS) binding with its ligand (cytosolic DNA) An et al, 2015) . Activated cGAS by binding to cytosolic DNA leads to production and binding of cGAMP to stimulator of interferon genes (STING), and thereby production of several cytokines especially type I interferons Zhang et al., 2014) . Recent findings revealed that palmitoyl-protein thioesterase 1 (PPT1) that is localized in lysosome, is a central target of HCQ to modulating of pH (Rebecca et al., 2019) . PPT1 enzyme cleaves and removes long-chain fatty acids called palmitate from proteins that are no longer required. PPT1 facilitates tumor growth via two downstream pathways including mTOR and autophagy (Rebecca et al., 2017) . Increasing body of evidence illustrated that HCQ potentially prevents tumor growth and inflammatory pathways (e.g RA) via inhibiting PPT1 ( Fig 1B) (Cook et al., 2014; Schrezenmeier & Dörner, 2020) . Recently, organic anion transporter family member 1A2 (OATP1A2) was identified as a novel target of HCQ (Xu et al., 2016) . OATP1A2, is a solute carrier transporter, expressed in a wide spectrum of tissues such as brain, liver, breast, testis, lung, kidney, and in retinal pigment epithelial (RPE) cells to regulate the transport and uptake of multiple substrates especially drugs and xenobiotics (Lee et al., 2005) . Collectively, HCQ by influencing multiple pathways supresses inflammation in several inflammatory diseases, infectious diseases, cancers, and recently SARS-CoV-2 infection.

It is becoming increasingly evident that HCQ may probably be a potential agent to combat SARS-CoV-2 . Previously, several studies revealed the antiviral effects of HCQ against some viruses such as HIV and influenza (Chiang et al., 1996; Ooi et al., 2006) .

Recently, various studies demonstrated that HCQ prevents SARS-CoV-2 from cell entry via several processes (Fig 2) . HCQ interferes with enzymes involved in glycosylation and activation of angiotensin converting enzyme (ACE) including glycosyltransferases and sugarmodifying enzymes, and consequently blocks virus-membrane fusion. Also, HCQ interferes with spike (S) protein glycosylation, and disrupts endosome-mediated virus cell fusion.

Moreover, HCQ impedes S protein cleavage which is a key point for cell fusion of SARS-CoV-2 by increasing lysosomal pH levels, and inhibiting its proteases (Gautret et al., 2020; Millet & Whittaker, 2015; Vincent et al., 2005; Yao et al., 2020) . Also, recent in vitro study showed that HCQ and CQ could decrease the viral replication in a concentration-dependent manner. Moreover, HCQ showed a higher safety and anti-SARS-CoV-2 efficacy relative to CQ (Yao et al., 2020) . HCQ may also prevent from SARS-CoV-2 spreading after cell entry through elevating `endosomal and lysosomal pH, and thereby preventing from activation of inflammation cascades (Srivatsan, 2020; Vincent et al., 2005) . Furthermore, pseudovirion colocalization with Niemann-Pick C1 (NPC1)-positive endolysosomes (LE/Lys) disclosed that HCQ could exert its antiviral effects through disturbance in SARS-CoV-2 replication (Srivatsan, 2020). Intriguingly, a study performed on HCQ mechanism of action illustrated that HCQ inhibits viral genome release by changing the number, size, and morphology of early endosomes or endolysosomes Mingo et al., 2015) . Furthermore, HCQ could diminish inflammation responses through several pathways including inhibiting MHC II-mediated T cell activation, inhibiting the release of cytokines such as IL-1, IL-6, TNF-α induced by T-cell activation, blockage of TLR signaling, stimulation of interferon genes (the STING pathway) by cGAS and thereby inhibiting cytokines release including I interferon, IL-1 and TNF-α induced by TLR and STING signaling ( Fig 1A and 1B) (Fox, 1996; Schrezenmeier & Dörner, 2020; Ireland & Unanue, 2011; Thwaites et al., 2014; An et al., 2015) . Therefore, anti-inflammatory mechanism of HCQ action created this hypothesis that it might be able to halt cytokine release syndrome, and reduce consequently organ damage especially lung, induced by COVID-19. There are some reports about the remarkable association between cytokine storm especially IL-6 and clinical and pathological manifestations of patients with SARS-CoV-2, serum SARS-CoV-2 viral load (RNAaemia), and mechanical ventilation requirement Gao et al., 2020; Herold et al., 2020; . Collectively, HCQ could exert its anti-COVID-19 effects via impeding virus' cell entry and post cell entry events such as viral replication, and inflammatory responses.

J o u r n a l P r e -p r o o f

HCQ is structurally different from CQ only by a hydroxyl group in its N-ethyl side chain (Finbloom et al., 1985) . CYP450 and its isoforms play a crucial role in HCQ and CQ metabolism (Stokkermans & Trichonas, 2019) . Both of them undergo some changes especially dealkylation by CYP isomers, and become converted into active metabolites (Furst, 1996; Projean et al., 2003) . Several investigations suggested that multiple CYP450

isoforms are involved in HCQ and CQ metabolism including CYP2C8, CYP3A4, CYP2D6, and CYP1A1 although the first three of them are more important relative to CYP1A1 (Fig 3) ( Li et al., 2003; Projean et al., 2003) . There is some evidence that administration of HCQ could interfere with other CYP-metabolized drugs such as metoprolol (Somer et al., 2000) .

Metoprolol is a beta blocker drug metabolized through CYP2D6 that is administered to prevent angina (chest pain) and manage high blood pressure. During HCQ and metoprolol combination therapy, HCQ interferes with metoprolol metabolism by competing for CYP2D6 (Somer et al., 2000) . Another drug-drug interaction that could take place is simultaneous administration of HCQ and methotrexate in management of RA. HCQ decreases the gastrointestinal absorption and bioavailability of methotrexate by modulating pH levels (Bannwarth et al., 1996) . Concurrent administration of low dose of CQ with cyclosporine was shown to cause a better treatment in patients with RA via synergic effects with cyclosporine, although significant renal dysfunction was observed (Landewé et al., 1998) . It's noteworthy to mention that HCQ could interfere with those drugs elevating gastric pH levels (e.g. H + /K + ATPase pump inhibitors) including omeprazole, lansoprazole, pantoprazole, esomeprazole, and rabeprazole (Namazi, 2009) . Therefore administration of HCQ in patients with COVID-19 that are simultaneously taking other mentioned drugs could lead to unwanted side effects.

NcRNAs such as miRNAs and lncRNAs affect post-transcriptionally the expression levels of several CYP genes, and thereby influence the metabolism, and bioavailability of CYP450mediated drugs (Jilek et al, 2017; Jin et al., 2016) . Moreover, DNA methylation and histone acetylation could affect the CYP-metabolized drugs through modulating CYP expression. J o u r n a l P r e -p r o o f

MiRNAs are a novel class of non-coding transcripts with 21-23 nucleotides length, and play a crucial role in a broad spectrum of disorders (Tiwar et al., 2018; Vishnoi & Rani, 2017) . In silico and in vitro (human embryonic kidney (HEK) 293T cells) investigation on effect of hsa-miR-25-3p on expression levels of CYP2B6 showed that hsa-miR-25-3p suppresses CYP2B6 expression by binding to CYP2B6 mRNA 3' UTR (Jin et al., 2016) . Furthermore, a study carried out on 24 patients with breast cancer (breast tumor and paired-normal tissue)

showed a negative association between expression levels of miR-27b and CYP1B1. Also, it showed that CYP1B1 contrary to miR-27b is highly expressed in cancerous tissues. CYP1B1

is expressed in estrogen-regulated tissues through catabolism of various procarcinogens, and 4-hydroxylation of 17β-estradiol (Tsuchiya et al., 2006) . Accumulating evidence showed that the expression levels of CYP2D6 which have a fundamental role in HCQ metabolism is influenced by several miRNAs (Pan et al., 2017; Zeng et al., 2017) . Surprisingly, a study performed on SH-SY5Y, and U251 cell lines demonstrated that testosterone could decrease CYP2D6 activity by increasing the level of miR-101 and miR-128-2 which bind to the 3′ UTR of CYP2D6 mRNA (Li et al., 2015) . (Li et al., 2015) . The high levels of cholesterol in rat induce the expression and binding of Lnc-Hc, a hepatocyte-specific lncRNA, to hnRNPA2B1. Lnc-HC/ hnRNPA2B1 complex inhibits cholesterol-bile acid conversion by decreasing CYP7A1 (Fig 4B) (Lan et al., 2016) .

DNA methylation and histone acetylation are the important epigenetic modifications that cells use to control gene expression of large number of genes (Verdone et al., 2006; Razin & Kantor, 2005) . In this view, CYP might be influenced by other epigenetic mechanisms such as DNA methylation, and histone modification . Isoniazid induced promoter methylation of CYP1A1 and CYP1B1 resulted in their downregulation and liver injury promotion in rat. Indeed, liver injury occurs probably due to upregulation of TLR4, extracellular-signal-regulated kinase (ERK), peroxisome proliferator-activated receptor (PPAR)-γ, IL-6, and TNF-α, caused by decreasing levels of CYP1A1 and CYP1B1 (Li et al., 2018) . Human hepatoma cell line HepG2 were treated with 5-aza-2'-deoxycytidine that inhibits DNA methylation, and trichostatin A that inhibits histone deacetylation caused expression changes in a wide spectrum of genes such as xenobiotic metabolism (CYP3A4, CYP3A5, and CYP3A7), and steroid biosynthesis (CYP17A1 and CYP19A1) genes (Dannenberg & Edenberg, 2006) . Trichostatin A is an antitumor drug that was shown to induce apoptosis in HepG2 cells through histone H3 acetylation of CYP2E1 promoter.

Trichostatin A-mediated CYP2E1 upregulation promotes apoptosis and antitumor effects by producing mitochondrial reactive oxygen species (Fig 4C) (Yang et al., 2010) .

Astonishingly, the pro-inflammatory cytokine IL-6 that plays a fundamental role in promoting colorectal cancer, was shown to increase the expression levels of CYP1B1 in vitro and therefore mediates the metabolic activation of pro-carcinogens, which may lead to generation of reactive metabolites capable of damaging DNA by genome-wide methylation of miR-27b promoter (Patel et al., 2014) . It seems that epigenetic mechanisms including 

Light sensitivity is an essential process to intact vision (Garway-Heath et al., 2000) .

Permanent sensitivity to light is provided by ongoing generation and condensation of rhodopsin on the photoreceptor outer segment discs by rough endoplasmic reticulum and

Golgi apparatus (Papermaster & Schneider, 1982; Ritter et al., 2008) . Photoreceptor inner segment supports the outer segment by supplying necessary substances. Also, the photoreceptor inner segment facilitates the elongation of photoreceptor outer segment toward RPE by continuous synthesis of discs (Chen et al., 2009) . A study conducted on retinal photoreceptors of multiple animal models including rhesus monkey, eastern gray squirrels, and California ground squirrels showed that photoreceptor outer segments are growing and extending continuously (Steinberg et al., 1980) . RPE cells protect photoreceptor outer segments via phagocytosis of the outer segment redundancies of photoreceptors (Chen et al., 2009 ). RPE cells are playing a crucial role in maintenance of photoreceptors stability by transporting nutrients, electrolytes, ions, and water to the retina, and choroid capillaries .

shown to be correlated with dystrophic retina . RPE cells prevent the accumulation of debris in photoreceptor outer segments by scavenging debris, and thereby causing rhodopsin cells renewal. RPE cells transfection with mer tyrosine kinase (MERTK) siRNA resulted in phagocytosis inhibition, due to downregulation of MERTK which is involved in RPE phagocytosis activity (Strick et al., 2009) . Correspondingly, Mertk mutated Royal College of Surgeons rats were diagnosed with autosomal recessive retinitis pigmentosa which emphesized on the fundamental role of phagocytosis activity of RPE cells in visual intact function .

The 4-aminoquinoline derivatives such as HCQ and CQ might cause retinopathy by affecting the lysosomal function, digestion ability of phagocytes, and binding to the melanin (Browning, 2014; Lee et al., 2015) . HCQ and CQ enter the lysosome and inactivate its enzymes including N-acetyl-β-glucosaminidase, and cathepsin D through alteration of its J o u r n a l P r e -p r o o f vital acidic condition (Toimela et al., 1995) . Moreover, HCQ and CQ cause massive aggregation of lysosomal associated organelles, membranous cytoplasmic bodies, and lipofuscin in RPE neuron cells by reducing the lysosomal acidic potency (Mahon et al., 2004) . Ongoing accumulation of lipofuscin in the RPE cells induces a positive feedback resulting in more accumulation of lipofuscin. Progressive aggregation of lipofuscin gradually damages RPE cells, and may cause several diseases such as age-related macular degeneration, and Stargardt disease (Dorey et al., 1989; Wolf, 2003) . In addition, lipofuscins aggregation in RPE cells may reduce the normal supportive function of RPE cells by disrupting organelle's cytoplasmic trafficking (R Sparrrow et al., 2010; Terman & Brunk, 2004) . Growing evidence suggest that HCQ promotes retinopathy by binding tightly to melanin in RPE. Furthermore, the strong binding of HCQ to melanin in other tissues including skin and ciliary bodies was shown to cause severe disorders such as skin hyperpigmentation (Fig 5) (Ding et al., 2016; Tracy et al., 2013) .

Visual cycle is a vital process to visual perception that is conducted by engaging transporters and binding proteins (Thompson & Gal, 2003) . Visual cycle exchanges vitamin A compounds (retinol) and facilitates signal transduction via providing substrates to the photoreceptors (Bok, 1993) . Carrier organic anion transporter 1A2 (SLCO1A2) encodes OATP1A2 which participates in retinol circulation (Kalliokoski & Niemi, 2009) . Increasing evidence suggest that OATPs have a fundamental role in the endogenous and exogenous substances influx into several organs including liver (OATP1B1), kidney, intestine, brain, and liver (OATP1A2) (Zaïr et al., 2008) . OATP1B1 is the most important transporter expressed in hepatocytes and is localized in the sinusoidal membrane of hepatocytes.

OATP1A2 is located in RPE apex, and mediates the transport of all-trans-retinol (atROL) from the interphotoreceptor matrix to the RPE (Chan et al., 2015) . Interestingly, HCQ and CQ probably disrupt the activity of OATP1A2 in transporting of atROL influx by competing with atROL to occupation of OATP1A2. Consequently, atROL accumulates within the interphotoreceptor matrix, and results in deficiency of 11-cis-retinal (11cRAL) and

rhodopsin, and thereby caused impaired vision (Xu et al., 2016) .

J o u r n a l P r e -p r o o f

The current novel SARS-CoV-2 has been widely spread throughout the world (203 countries) with high mortality and morbidity (2020a). A global effort is underway to find a potential drug to counter SARS-CoV-2 (2020b). Recently, growing body of evidence showed that HCQ might be a potential drug to counteract the novel coronavirus (Gautret et al., 2020; Yao et al., 2020) . HCQ and CQ were administrated to patients affected with infectious diseases (HIV and influenza), and immune diseases (RA and SLE) (Chiang et al., 1996; Ooi et al., 2006; Rainsford et al. 2015) . Several investigations have reported that HCQ has a higher safety and anti-viral activity to combat COVID-19 in comparison with CQ (Yao et al., 2020; . In this contex, an in vitro study carried out on African green monkey kidney Vero cells infected by SARS-CoV-2 and treated with HCQ and CQ showed that both of them decreased the viral replication in a concentration-dependent manner although HCQ showed a larger in vitro antiviral effects relative to CQ (Yao et al., 2020 ). An investigation conducted in Shanghai, China, on 30 confirmed cases with COVID-19

including 15 cases that were given conventional treatment and 15 cases that were given 400 mg per day HCQ along with conventional treatment for 5 days revealed the similar frequency of negative patients for nasopharyngeal swabs test of COVID-19 on day 7 after treatment between two groups. Also, the median time of normalization of body temperature was similar in both groups, whereas worsening computerized tomography findings of lung were seen in 5 patients (33.3%) of case group and 7 subjects (46.7%) of control group . A clinical trial study performed on 36 French confirmed SARS-CoV-2 cases (6 patients left the study) including 20 cases that were given HCQ (600 mg/day) (6 of them received azithromycin (500 mg on day 1 followed by 250 mg/day, the next four days) along with HCQ), and 16 cases receiving neither HCQ nor azithromycin illustrated a positive effect of combination therapy on ameliorating clinical manifestations. Surprisingly, their findings demonstrated that the nasopharyngeal PCR test at days 6 after treatment was negative for 100% of cases that underwent combined therapy whereas only 57% of patients that received HCQ only, and 12.5% of control group patients showed a negative nasopharyngeal PCR test (Gautret et al., 2020) . The discrepancy between results of Shanghai and French study may be due to small sample size in both study or combination of HCQ and azithromycin in the French study in comparison with Shanghai study which used conventional and HCQ treatment. Strikingly, the achieved results from study performed on 11 patients affected with J o u r n a l P r e -p r o o f SARS-CoV-2 (7 men and 4 women) that 8 had significant comorbidities associated with poor outcomes (obesity: 2; solid cancer: 3; hematological cancer: 2; HIV-infection: 1) have shown an inconsistent finding about co-administration of azithromycin and HCQ (the dosage was similar to French study) in comparison with French study. It was revealed that one patient died, two were transferred to the ICU, and therapy was discontinued in one patient due to prolongation of the QT interval. Also, PCR test from nasopharyngeal swabs of 10 patients who were alive showed a positive SARS-CoV-2 finding in 8 of them on day 5 to 6 post treatment (Molina et al., 2020) . Different response of patients affected with COVID-19 to HCQ supports the hypothesis that different CYP SNPs and epigenetic mechanisms might be responsible for different HCQ metabolism, and therefore different response. The CYP450

and its isoforms have a key role in metabolism and conversion of HCQ into pharmacologically active substances (Stokkermans & Trichonas, 2019 (Lee et al., 2016) . Besides, several studies reported multiple drug-drug interactions for HCQ and other drugs including metoprolol, methotrexate, cyclosporine, and H + /K + ATPase pump inhibitors (omeprazole, lansoprazole, pantoprazole, esomeprazole, and rabeprazole) (Bannwarth et al., 1996; Landewé et al., 1998; Namazi, 2009; Somer et al., 2000) . cramps, and dysgeusia), central nervous system disorders (headaches, dizziness, anxiety, and rarely psychosis and convulsions), skin disorders (rash and discoloration), and retinopathy (Ali & Jones, 2018; Joyce et al., 2013; Pelle & Callen, 2002) . Administation of higher dosage of HCQ in patients with SARS-CoV-2 raised the possiblity that HCQ induced-side effects may probably take place more rapidly. On the other hand, studies showed that retinopathy induced by HCQ could progress and become irreversible even after drug cessation in some patients (Pandya et al., 2015; Yusuf et al., 2017 J o u r n a l P r e -p r o o f 

23. An adverse neuropsychiatric reaction following treatment with hydroxychloroquine: A case report

Inhibition of Cyclic GMP-AMP Synthase Using a Novel Antimalarial Drug Derivative in Trex1-Deficient Mice

Novel anti-malarial drug derivative inhibited type I interferon production and autoimmune inflammation through inhibition of cGAS-STING pathway in trex1−/− mouse

Cutting edge: antimalarial drugs inhibit IFN-β production through blockade of cyclic GMP-AMP synthase-DNA interaction

Chloroquine levels in blood during chronic treatment of patients with rheumatoid arthritis

Clinical pharmacokinetics of lowdose pulse methotrexate in rheumatoid arthritis

Hydroxychloroquine: from malaria to autoimmunity

The retinal pigment epithelium: a versatile partner in vision

Toxicology of hydroxychloroquine and chloroquine and the pathology of the retinopathy they cause

Human organic anion transporting polypeptide 1A2 (OATP1A2) mediates cellular uptake of all-trans-retinol in human retinal pigmented epithelial cells

Dysfunction of the retinal pigment epithelium with age: increased iron decreases phagocytosis and lysosomal activity

A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19. Zhejiang Da Xue Xue Bao Yi Xue Ban

Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients

Inhibition of HIV-1 replication by hydroxychloroquine: mechanism of action and comparison with zidovudine

Hydroxychloroquine: a physiologically-based pharmacokinetic model in the context of cancer-related autophagy modulation

Chloroquine inhibits autophagy to potentiate antiestrogen responsiveness in ER+ breast cancer

Pharmacokinetics and cellular uptake of 4-aminoquinoline antimalarials

Mutation of the receptor tyrosine kinase gene Mertk in the retinal dystrophic RCS rat

Epigenetics of gene expression in human hepatoma cells: expression profiling the response to inhibition of DNA methylation and histone deacetylation

Hydroxychloroquine-related retinal toxicity

Cell loss in the aging retina. Relationship to lipofuscin accumulation and macular degeneration

Comparison of hydroxychloroquine and chloroquine use and the development of retinal toxicity

Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development

Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases

Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19

Mapping the visual field to the optic disc in normal tension glaucoma eyes

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Level of IL-6 predicts respiratory failure in hospitalized symptomatic COVID-19 patients

Autophagy in antigen-presenting cells results in presentation of citrullinated peptides to CD4 T cells

Effects of microRNA-34a on the pharmacokinetics of cytochrome P450 probe drugs in mice

MicroRNA hsa-miR-25-3p suppresses the expression and drug induction of CYP2B6 in human hepatocytes

Hydroxychloroquine cardiotoxicity presenting as a rapidly evolving biventricular cardiomyopathy: key diagnostic features and literature review

Impact of OATP transporters on pharmacokinetics

Phagocytosis of retinal rod and cone photoreceptors

Retinopathy due to antimalarial drugs in patients with connective tissue diseases: are they so innocent? A single center retrospective study

Mode of action of hydroxychloroquine in RA-evidence of an inhibitory effect on Toll-like receptor signaling

The effects of CKD on cytochrome P450-mediated drug metabolism

A novel long noncoding RNA Lnc-HC binds hnRNPA2B1 to regulate expressions of Cyp7a1 and Abca1 in hepatocytic cholesterol metabolism

Combination therapy in recent onset rheumatoid arthritis: a randomized double blind trial of the addition of low dose cyclosporine to patients treated with low dose chloroquine

Transfer of chloroquine and desethylchloroquine across the placenta and into milk in Melanesian mothers

Pericentral hydroxychloroquine retinopathy in Korean patients

Association of polymorphisms of cytochrome P450 2D6 with blood hydroxychloroquine levels in patients with systemic lupus erythematosus

Polymorphisms in Human Organic Anion-transporting Polypeptide 1A2 (OATP1A2) implications for altered drug disposition and central nervous system drug entry

Regulation of cytochrome P450 expression by microRNAs and long noncoding RNAs: Epigenetic mechanisms in environmental toxicology and carcinogenesis

Sex hormones regulate cerebral drug metabolism via brain miRNAs: down-regulation of brain CYP 2 D by androgens reduces the analgesic effects of tramadol

Identification of human cytochrome P 450 s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data

Current trends in drug metabolism and pharmacokinetics

Cytochrome P450 1A1 and 1B1 promoter CpG island methylation regulates rat liver injury induced by isoniazid

Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

Covid-19: six million doses of hydroxychloroquine donated to US despite lack of evidence

Chloroquine causes lysosomal dysfunction in neural retina and RPE: implications for retinopathy

Metabolism of chloroquine-3-14C in the rhesus monkey

Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate

Host cell proteases: Critical determinants of coronavirus tropism and pathogenesis

Ebola virus and severe acute respiratory syndrome coronavirus display late cell entry kinetics: evidence that transport to NPC1+ endolysosomes is a rate-defining step

No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection

Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation

The potential negative impact of proton pump inhibitors on the immunopharmacologic effects of chloroquine and hydroxychloroquine

In vitro inhibition of human influenza A virus replication by chloroquine

Cholic acid feeding leads to increased CYP2D6 expression in CYP2D6-humanized mice

Hydroxychloroquine retinopathy: a review of imaging

Biosynthesis and morphogenesis of outer segment membranes in vertebrate photoreceptor cells

Interleukin-6 mediated upregulation of CYP1B1 and CYP2E1 in colorectal cancer involves DNA methylation, miR27b and STAT3

Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus

Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: a timely review

In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation

The retinal pigment epithelium in health and disease

Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases

DNA methylation in epigenetic control of gene expression

PPT1 promotes tumor growth and is the molecular target of chloroquine derivatives in cancer

A unified approach to targeting the lysosome's degradative and growth signaling roles

Activity switches of rhodopsin

Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology

Influence of hydroxychloroquine on the bioavailability of oral metoprolol

Potential dual therapeutic approach against SARS-CoV-2/COVID-19 with Nitazoxanide and Hydroxychloroquine

Disc morphogenesis in vertebrate photoreceptors

Mertk drives myosin II redistribution during retinal pigment epithelial phagocytosis

Chloroquine And Hydroxychloroquine Toxicity

Different effects of chloroquine and hydroxychloroquine on lysosomal function in cultured retinal pigment epithelial cells

Epigenetic regulation of cytochrome P450 enzymes and clinical implication

Antimalarials in rheumatic diseases

Vitamin A metabolism in the retinal pigment epithelium: genes, mutations, and diseases

Emerging role of endosomal Toll-like receptors in rheumatoid arthritis

MicroRNA key to angiogenesis regulation: miRNA biology and therapy

Retinal pigment epithelium cell culture as a model for evaluation of the toxicity of tamoxifen and chloroquine

Hydroxychloroquine-induced hyperpigmentation

MicroRNA regulates the expression of human cytochrome P450 1B1

Histone acetylation in gene regulation

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread

MiRNA biogenesis and regulation of diseases: an overview

The HNF1α-regulated lncRNA HNF1α-AS1 is Involved in the Regulation of Cytochrome P450 Expression in Human Liver Tissues and Huh7 Cells

Hydroxychloroquine is much less active than chloroquine against chloroquine-resistant Plasmodium falciparum, in agreement with its physicochemical properties

Lipofuscin and macular degeneration

Chloroquine and hydroxychloroquine are novel inhibitors of human organic anion transporting polypeptide 1A2

Histone modification-mediated CYP2E1 gene expression and apoptosis of HepG2 cells

In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Effect of hydroxychloroquine on the inflammation in antigen presenting cells interacted with damaged corneal epithelial cells

Hydroxychloroquine retinopathy

Pharmacogenetics of OATP (SLC21/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney

MicroRNA hsa-miR-370-3p suppresses the expression and induction of CYP2D6 by facilitating mRNA degradation

The cytosolic DNA sensor cGAS forms an oligomeric complex with DNA and undergoes switch-like conformational changes in the activation loop

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Authors declare no conflict of interest.

HCQ: hydroxychloroquine; CQ: chloroquine. J o u r n a l P r e -p r o o f